Litvinov S V, Remennik I V, Kriukova I N
Biull Eksp Biol Med. 1984 May;97(5):600-3.
Indirect radioimmunoassay and immunoperoxidase studies provided further evidence of human serum reactivity with murine mammary tumor virus (MMTV) structural proteins. Examination of over 400 human sera from breast cancer (BC) patients and controls has shown that the incidence of antibodies which react with MMTV structural proteins was significantly higher in BC patients (50%) than in patients with carcinomas of other organs (3%) or normal women (3%). However, the percentage of subjects immune to MMTV was higher in pregnant women (10%) as compared with normal subjects. All the women with BC of the first clinical stage had antibodies to MMTV. The percentage of immune donors was lower among patients with BC of the later stages (IIa, 90%, IIb, 76%, III, 27%, IV, 0%). Thus, a good agreement has been demonstrated between the first stages of BC and expression of antibodies to MMTV.
间接放射免疫测定和免疫过氧化物酶研究进一步证明了人血清与小鼠乳腺肿瘤病毒(MMTV)结构蛋白的反应性。对400多名乳腺癌(BC)患者和对照的人血清进行检测发现,与MMTV结构蛋白发生反应的抗体发生率在BC患者中(50%)显著高于其他器官癌患者(3%)或正常女性(3%)。然而,与正常受试者相比,孕妇中对MMTV免疫的受试者百分比更高(10%)。所有处于第一临床阶段的BC女性均有针对MMTV的抗体。在晚期BC患者(IIa期,90%;IIb期,76%;III期,27%;IV期,0%)中,免疫供体的百分比更低。因此,已证明BC的第一阶段与针对MMTV抗体的表达之间存在良好的一致性。